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Brain APOE expression quantitative 
trait loci-based association study 
identified one susceptibility 
locus for Alzheimer’s disease by 
interacting with APOE ε4
Aiqian Zhang1, Qingnan Zhao2, Dabao Xu1 & Shan Jiang3
Some studies have demonstrated interactions of AD-risk single nucleotide polymorphisms (SNPs) in 
non-APOE regions with APOE genotype. Nevertheless, no study reported interactions of expression 
quantitative trait locus (eQTL) for APOE with APOE genotype. In present study, we included 9286 
unrelated AD patients and 8479 normal controls from 12 cohorts of NIA Genetics of Alzheimer’s Disease 
Data Storage Site (NIAGADS) and Alzheimer’s Disease Neuroimaging Initiative (ADNI). 34 unrelated 
brain eQTLs for APOE were compiled from BRAINEAC and GTEx. We used multi-covariate logistic 
regression analysis to identify eQTLs interacted with APOE ε4. Adjusted for age and gender, substantia 
nigra eQTL rs438811 for APOE showed significantly strong interaction with APOE ε4 status (OR, 1.448; 
CI, 1.124–1.430; P-value = 7.94 × 10−6). APOE ε4-based sub-group analyses revealed that carrying 
one minor allele T of rs438811 can increase the opportunity of developing to AD by 26.75% in APOE ε4 
carriers but not in non-carriers. We revealed substantia nigra eQTL rs438811 for APOE can interact with 
APOE ε4 and confers risk in APOE ε4 carriers only.
Alzheimer’s Disease (AD) is the most common form of dementia with strong genetic etiology. Apolipoprotein 
E (APOE) ε4 allele has been universally confirmed as a strong risk factor for Late-Onset Alzheimer’s Disease 
(LOAD)1,2. APOE4, the isoform of APOE determined by ε4 allele, differs with other two isoforms APOE2 and 
APOE3 at protein structure, lipid association and receptor binding3. In most, if not all, putative AD pathogenic 
pathways, APOE4 either diminishes neuroprotection or augments neurotoxicity when compared with other two 
isoforms. These evidences which could explain the AD pathogenic nature of APOE4 include: APOE4 impairs 
synaptic repair and plasticity4,5; might be less efficient in transporting brain cholesterol6,7; increases Aβ aggre-
gation and impairs clearance8,9; increases formation of neurofibrillary tangles10; decreases metabolic activity of 
neurons11.
Although APOE4 is neurotoxic remarkably and miscellaneously, not all APOE ε4 carriers developed to AD in 
a population, even for carriers of APOE ε4 homozygotes12. Likewise, not all APOE ε4 non-carriers are intact from 
AD. Except for APOE ε4, other genes were also identified to be associated with AD by genome-wide association 
studies (GWASs) in recent years13–15. Interestingly, Jun et al. revealed interaction of one of these susceptible genes 
PICALM with APOE ε4 on AD risk—genotypes at PICALM confer risk predominantly in APOE ε4 non-carriers16. 
In addition, GAB2 and some other genes can also modify AD risk by interacting with APOE ε417–19. Seemingly, 
these APOE ε4-interactive genes can give some reasons for the imperfect effect of APOE ε4, nevertheless, all of 
them are in non-APOE regions. Until now, no study has reported interactions of single nucleotide polymor-
phisms (SNPs) in APOE regulatory region with APOE genotypes, especially brain expression quantitative trait 
loci (eQTLs) for APOE. We speculate that some brain eQTLs can be related to AD by potentially regulating 
expression level of APOE ε4.
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This study was aimed at identifying brain eQTLs for APOE which can interact with APOE ε4 allele to confer 
AD risk.
Results
Characteristics of included GWAS cohorts after related individual removal. Across the 13 GWAS 
cohorts, 1,320 AD patients and 1,502 healthy controls were identified by KING as duplicate samples or kin with a 
third degree (e.g. first cousin) or closer relationship. After excluding these samples, 9,286 unrelated AD patients 
and 8,479 healthy controls were retained.
Description of the 12 GWAS cohorts from NIA Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS) 
and GWAS data from Alzheimer’s Disease Neuroimaging Initiative (ADNI) after related individual removal is 
shown in Table 1.
Brain tissue-specific eQTLs for APOE and determination of proxy SNPs. We collected 73 brain 
tissue-specific eQTLs from BRAINEAC (http://www.braineac.org/) and GTEx (https://www.gtexportal.org/home/). 
34 out of the 73 eQTLs were determined by LDproxy (https://analysistools.nci.nih.gov/LDlink/?tab = ldproxy) as 
proxy eQTLs.
After excluding low-quality imputed eQTLs with imputation info score less than 0.9, all 34 proxy eQTLs were 
retained for further analysis. For the detailed information of the 34 proxy eQTLs, please refer to Table S1.
rs438811 confers risk in APOE ε4 carriers predominantly. We used multivariate logistic regression 
analysis to identify eQTLs which can confer AD risk in the 34 proxy eQTLs for APOE. After adjustment for age 
and gender, substantia nigra eQTL rs438811 (odds ratio [OR], 2.343; 95% confidence interval [CI], 2.205–2.490; 
raw P-value = 7.49 × 10−167) was associated with AD (Table 2). After adjustment for age, gender and APOE ε4 
status, rs438811 (OR, 1.049; 95% CI, 0.969–1.135; P-value = 0.237) was not associated with AD (Table 2). After 
introducing interaction item rs438811 genotype × APOE ε4 status into the model, rs438811 was found can confer 
AD risk by interacting with APOE ε4 status strongly (OR, 1.448; 95% CI, 1.231–1.704; P-value = 7.94 × 10−6; 
Table 3). Sub-group analysis showed rs438811 confer risk predominantly in APOE ε4 carriers (OR, 1.267; 95% CI, 
1.124–1.430; P-value = 1.12 × 10−4; Table 3), which indicates carrying one minor allele T of rs438811 can increase 
the opportunity of developing to AD by 26.75% in APOE ε4 carriers. As shown in BRAINEAC, minor allele T of 
rs438811 was associated with increased APOE expression level in substantia nigra. The APOE eQTL P-values of 
rs438811 across the ten different brain regions were shown in Table S2.
Abbreviated cohort name* Ancestry Cases/controls Female (%) Presence of APOE ε4 (%)
NIA-LOAD mixed, 92.33% caucasian 993/884 62.30% 52%
ADC1 caucasian 1574/527 55.30% 57.90%
ADC2 caucasian 745/165 54.20% 55.10%
ADC3 caucasian 862/618 54.20% 40.70%
UPITT mixed, 91.73% caucasian 1424/996 63.80% 42.20%
TGEN II caucasian 1013/585 54.20% 48.50%
ROSMAP caucasian 368/1326 69.10% 23.30%
WashU1 caucasian 403/225 58.10% 43.60%
MIRAGE caucasian 603/885 59.70% 38.90%
ACT unknown 567/1701 57.70% 26.10%
UMVUMSSM unknown 1240/1230 62.50% 37.90%
MAYO caucasian 841/1253 53.40% 42.70%
ADNI mixed, 92.88% caucasian 213/347 47% 41.60%
Table 1. Cohort description. *Cohort full names: NIA-LOAD, National Institute on Aging Genetics Initiative 
for Late-Onset Alzheimer’s Disease; ADC1, Alzheimer’s Disease Center Dataset 1; ADC2, Alzheimer’s Disease 
Center Dataset 2; ADC3, Alzheimer’s Disease Center Dataset 3; UPITT, University of Pittsburgh; TGEN II, 
Translational Genomics Research Institute II; ROSMAP, Religious Orders Study and Memory and Aging 
Project; WashU1, Washington University Dataset 1; MIRAGE, Multi Institutional Research on Alzheimer 
Genetics Epidemiology; ACT, Adult Changes in Thought; UMVUMSSM, University of Miami (UM), Vanderbilt 
University (VU) and Mount Sinai School of Medicine (MSSM); ADNI, Alzheimer’s Disease Neuroimaging 
Initiative.
SNP Minor allele MAF*
Adjusted for age and gender
Adjusted for age, gender and 
APOE ε4 status
OR (95% CI) P-value OR (95% CI) P-value
rs438811 T 0.287 2.343 (2.205–2.490) 7.49 × 10−167 1.049 (0.969–1.135) 0.237
Table 2. Substantia nigra eQTL rs438811 for APOE identified as a susceptibility locus for AD. *Weighed-
average minor allele frequency.
www.nature.com/scientificreports/
3SCienTifiC RePoRTS |  (2018) 8:8068  | DOI:10.1038/s41598-018-26398-1
By querying Encyclopedia of DNA Elements (ENCODE), rs438811 was found to be target of transcription 
factors POLR2A and RPC155. rs483082, a brain eQTL for APOE which is in complete linkage with rs438811 and 
was also identified can interact with APOE ε4 status to confer AD risk in this study, was the target of multiple 
transcription factors: HNF4G, CEBPB, MXI1, HDAC2, SP1, RFX5, MAX, EP300, JUND, FOSL2, ZBTB7A and 
CEBPD. rs483082 was also found be to located in a DNase I hypersensitivity cluster.
Discussion
APOE has long been a widely-investigated gene since the identification of its association with AD. Many studies 
have reported the relations between APOE genotypes and AD-related traits, such as cerebral spinal fluid (CSF) 
biomarkers20–22, brain morphology changes23–25, and particular cognitive measures23,26,27. However, except for 
APOE ε4, no locus encompassing the APOE region, including brain eQTLs for APOE, were identified as a confer-
ring risk for AD or AD-related traits. This study identified AD risk-associated brain eQTL for APOE by incorpo-
rating multiple GWAS cohorts.
The susceptibility locus rs438811 identified is in complete linkage with another brain eQTL for APOE–
rs483082–which was associated with AD in summary statistics of International Genomics of Alzheimer’s pro-
ject (IGAP) and was reported to associate with AD in a Japanese population15,28. rs483082 was also associated 
with AD and confer AD risk in APOE ε4 carriers only in this study (data not shown). Furthermore, rs483082 
was also reported to associate with lipid level29. Abnormal lipid metabolism has long been demonstrated to as 
being involved in AD pathology30–32. Our results revealed that the eQTL may influence the progression of AD 
APOE ε4 carriers by increasing the expression level of APOE. -491A/T, or rs449647, a polymorphism located 
in APOE transcriptional regulatory region, is the earliestly-reported APOE expression-associated variant by 
luciferase/β-galactosidase activity assay related to AD independent of APOE ε4 dosage33. In contrast to the ear-
liest AD-associated APOE eQTL, the APOE eQTL identified in this study affect APOE expression in a brain 
region-specific manner. We also analyzed the association of -491A/T with AD (Table S3) and its interactive 
effect with APOE ε4 status on AD risk (Table S4). In consistent with the result from the study applied lucif-
erase/β-galactosidase activity assay33, −491A/T confer AD risk independent of APOE ε4 status. rs438811 is a sub-
stantia nigra-specific APOE eQTL. As a brain substructure dysfunction of which contributes to extrapyramidal 
signs (EPS), pathological changes of substantia nigra are responsible for EPS and aggravated EPS in AD patients34. 
As to how the brain APOE eQTL influence the progression of AD, one most probable explanation is the neuro-
toxic effect of increased APOE4 expression level in substantia nigra. Nevertheless, pathological mechanism of the 
brain APOE eQTL still needs to be unveiled by molecular biological experiments.
In summary, this is a pilot study associating brain APOE eQTLs to AD risk. It identified a novel SNPs associ-
ated with AD by interacting with APOE ε4 status and potentially regulating expression level of APOE.
Methods
Compiling of brain APOE eQTLs. Brain APOE eQTLs studied in this multi-cohort gene-wide associa-
tion study were collected by querying BRAINEAC (http://www.braineac.org/) and GTEx (https://www.gtexpor-
tal.org/home/) databases. BRAINEAC provides the gene expression across ten brain tissues (cerebellar cortex, 
frontal cortex, hippocampus, medulla, occipital cortex, putamen, substantia nigra, thalamus, temporal cortex 
and intralobular white matter) from 134 healthy control individuals. GTEx provides the gene expression across 
thirteen brain tissues (amygdala, anterior cingulate cortex, caudate, cerebellar hemisphere, cerebellum, cortex, 
frontal cortex, hippocampus, hypothalamus, nucleus accumbens, putamen, spinal cord and substantia nigra) with 
the sample sizes ranged from 80 to 154. The cis brain eQTLs with P-values less than 1 × 10−3 and located within 
up- or down-stream 10 Mb boundary of the APOE gene were retrieved from the two eQTL databases. To reduce 
redundant computation for the AD association analysis, brain eQTLs within the same linkage disequilibrium 
(LD) block were pruned and one eQTL was chosen to serve as the proxy for the LD block. Proxy brain eQTLs 
were determined by LDproxy (https://analysistools.nci.nih.gov/LDlink/?tab=ldproxy) with a threshold of LD 
r2 ≥ 0.8.
Subjects. In this study, we included a total of 13 AD GWAS cohorts. 12 out of them were from NIAGADS. 
The criteria for inclusion of cohorts from NIAGADS was carrying covariate information on age, gender and 
APOE genotype. For detailed information on the 12 cohorts from NIAGADS, please refer to Table S5. The last 
cohort was from ADNI. GWAS data from ADNI were generated as previously described and obtained from the 
ADNI database (http://www.loni.ucla.edu/ADNI/)35. Finally, a total of 10606 AD patients and 9981 healthy con-
trols were included in this study.
Identification and exclusion of related individuals. We used KING to identify and exclude duplicate 
samples and kin with a third degree (e.g. first cousin) or closer relationship within and across datasets36.
Quality control of chromosome 19. For the purpose of imputation, we extracted all SNPs in chromo-
some 19, where APOE is located, from each GWAS dataset. Standard quality control was then applied using Plink 
SNP
APOE ε4 carriers* APOE ε4 non-carriers* SNP × APOE ε4 status interaction*
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
rs438811 1.267 (1.124–1.430) 1.12 × 10−4 0.882 (0.788–0.986) 0.028 1.448 (1.231–1.704) 7.94 × 10−6
Table 3. Interactive effect of substantia nigra eQTL rs438811 for APOE with APOE ε4 status on AD risk. 
*Adjusted for age and gender.
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1.937. For each dataset, SNPs with a call rate of less than 99%, minor allele frequency of less than 1% and violation 
of Hardy-Weinberg equilibrium in controls (P < 1 × 10−4) were removed. Samples with a call rate of less than 90% 
were removed.
Imputation of chromosome 19. Because all the brain eQTLs collected in this study are cis eQTLs which 
are located within up- or down-stream 10 Mb boundary of the APOE gene, only chromosome 19 was imputed to 
reduce computation burden. The SNPs of chromosome 19 were prephased using SHAPEIT2 for each dataset38. 
SNPs were then imputed to a reference panel of 1000 Genome Project Phase 3 by IMPUTE239. An imputation info 
score cutoff of 0.9 was applied to exclude low-quality imputed SNPs. After imputation, collected eQTLs from the 
two databases for brain tissues were extracted.
Identification of population substructure. To adjust for confounding effect of population substructure 
in our data, we calculated eigenvectors of individuals through whole genome-wide principal component analysis 
(PCA) before chromosome 19 SNPs were extracted using Plink 1.937. All Principal components (PCs, from PC1 
to PC20) were used for confounding adjustment.
Combination of genotyped and imputed data. In this study, the genotyped and imputed brain eQTLs 
for APOE were inconsistent among different datasets. In order to combine all the GWAS datasets for AD associa-
tion analysis, imputed high-quality brain eQTL with high confidence (genotype probability greater than 0.8) were 
converted to be simulated genotype data by fcGENE for each individual40. Simulated genotype data were then 
combined with originally genotyped data.
Statistical analysis. After adjusting for age, gender and all PCs, these proxy brain eQTLs were tested for 
associations with AD with or without adjustment for APOE ε4 status through multivariate logistic regression 
analysis. eQTLs were coded as 0, 1, or 2 according to their number of minor alleles. APOE ε4 status was coded as 0 
or 1 according to absence (APOE ε2/2, ε2/3 and ε3/3 subjects) or presence (APOE ε2/4, ε3/4 and ε4/4 subjects) of 
APOE ε4. Interaction item SNP genotype × APOE ε4 status was then introduced into the model to investigate the 
interactive effect of SNP and APOE ε4 status on AD risk. To account for multiple testing, we used the Bonferroni 
correction and considered significant only those brain eQTLs for which P-value < 0.05/34 = 0.05/34 = 1.47 × 10−3. 
All statistical calculations were performed using R41.
Biological function annotation of identified APOE ε4 status-interactive brain eQTLs for APOE. 
Biological function annotation of identified APOE ε4 status-interactive brain eQTLs for APOE was performed via 
querying Encyclopedia of DNA Elements (ENCODE, https://www.encodeproject.org/).
Data availability statement. The brain eQTL data for APOE can be retrieved from Braineac (http://www.
braineac.org/) and GTEx (https://www.gtexportal.org/home/). The GWAS datasets used in this study can be 
applied and downloaded from NIAGADS (https://www.niagads.org/) and ADNI (http://adni.loni.usc.edu/).
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